BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 23224235)

  • 41. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
    Singh Ranger G
    J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
    Fentiman IS
    Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
    Ferreira AR; Palha A; Correia L; Filipe P; Rodrigues V; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; Lin NU; Costa L; Vaz-Luis I
    Breast; 2018 Feb; 37():107-113. PubMed ID: 29131988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
    Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
    Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
    Salmon RJ; Alran S; Malka I; de Cremoux P; Rosty C; Languille O; Campana F; ; Sigal-Zafrani B
    Am J Clin Oncol; 2006 Aug; 29(4):385-8. PubMed ID: 16891867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study.
    Schrading S; Schild H; Kühr M; Kuhl C
    Radiology; 2014 Apr; 271(1):45-55. PubMed ID: 24475835
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Three men with breast cancer].
    Bergs EA; Tanis PJ; Steller EP
    Ned Tijdschr Geneeskd; 2005 Mar; 149(10):534-7. PubMed ID: 15782690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
    He W; Fang F; Varnum C; Eriksson M; Hall P; Czene K
    J Clin Oncol; 2015 Jul; 33(20):2262-9. PubMed ID: 26033800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?
    Petrelli F; Barni S
    Clin Breast Cancer; 2015 Jun; 15(3):169-70. PubMed ID: 25600162
    [No Abstract]   [Full Text] [Related]  

  • 58. CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?
    Abreu MH; Gomes M; Menezes F; Afonso N; Abreu PH; Medeiros R; Pereira D; Lopes C
    Breast; 2015 Aug; 24(4):481-6. PubMed ID: 25963137
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
    He W; Smedby KE; Fang F; Olsson H; Margolin S; Hall P; Czene K
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28423398
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adherence in tamoxifen therapy after conversion to a rebate pharmaceutical in breast cancer patients in Germany.
    Kostev K; May U; Hog D; Eisel J; Kremmers T; Kosteic M; Waehlert L; Hadji P
    Int J Clin Pharmacol Ther; 2013 Dec; 51(12):969-75. PubMed ID: 24120719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.